The purpose of the Animal Models Core facility is to support and centralize certain aspects of the work in each project proposed. It is our belief that prostate cancer biology is best studied in animal model systems that allow experimental monitoring of progression events such as metastasis and androgen-independent progression. This facility brings together expertise in mouse genetics and human tumor xenografs that will allow basic molecular biological questions to be addressed in state-of-the art model systems with direct relevance to the clinical situation. It also offers an opportunity for translational research questions to be addressed immediately in relevant pre-clinical models. The Core consists of six distinct components which will allow biologically based hypotheses to be tested in Suitable animal models or human prostate cancer xenografts.
The Specific Aims of this Core are as follows: 1. To provide SCID mice to the five research projects 2. To propagate four human prostate cancer xenografts: LAPC4, LAPC9, CWR22, and LUCAP on SCID mice for Investigators in the SPORE. 3. To maintain model mice, such as Pten and Cox-2 conditional knock-out, AKT and Myc transgenic mice as well as reporter lines needed for each project. 4. To provide technical assistance for in vivo experiments, such as harvest xenografts, measure PSA level, and inject pro-drugs for pre-clinical trials. 5. To provide expertise/consultation on animal experimentation and surgical techniques required for the proposed studies. 6. To provide expertise/consultation for the generation of new models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-10
Application #
8291335
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2011
Total Cost
$87,349
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Lee, Ha Neul; Mitra, Mithun; Bosompra, Oye et al. (2018) RECK isoforms have opposing effects on cell migration. Mol Biol Cell 29:1825-1838
Aggarwal, Rahul; Huang, Jiaoti; Alumkal, Joshi J et al. (2018) Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503
Cheng, Larry C; Li, Zhen; Graeber, Thomas G et al. (2018) Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer. J Vis Exp :
Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95
Tan, Nelly; Shen, Luyao; Khoshnoodi, Pooria et al. (2018) Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol 199:1218-1223
Donin, Nicholas M; Reiter, Robert E (2018) Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 59:177-182
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82

Showing the most recent 10 out of 339 publications